Minggu, 17 April 2016

Widely Used Type 2 Diabetes Drug May Reduce Cancer Death Risk

Unknown     06.42  No comments

Metformin, a commonly prescribed diabetes drug, may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, a new study suggests.
The study found that for women with type 2 diabetes and cancer, the odds of dying from cancer appeared to be 45 percent higher compared to women with cancer who didn't have diabetes. But, in women with cancer who took metformin to treat their type 2 diabetes, the risk of dying from cancer seemed about the same as it was for women without diabetes.
"Our findings from this large study may provide more evidence that postmenopausal women with diabetes and cancer may benefit from metformin therapy compared to other anti-diabetes therapy," said lead researcher Zhihong Gong. She's an assistant professor of oncology at the Roswell Park Cancer Institute, in Buffalo, N.Y.

Unknown


Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Ut odio. Nam sed est. Nam a risus et est iaculis adipiscing. Vestibulum ante ipsum faucibus luctus et ultrices.
View all posts by Naveed →

0 komentar :

About U.S. Pharma Corporation

U.S. Pharma Corporation is headquartered in New Jersey but has research sites in Germany, France, the United Kingdong, Switzerland, and Australia. Research and development of new pharmaceuticals is key to ongoing profits, and U.S. Pharma researches and tests thousands of possible drugs. The company’s researchers need to share information with others within and outside the company, including the U.S. Food and Drug Administration, the World Health Organization, and the International Federation of Pharmaceutical Manufactureres & Associations. Also critical is Access to health information sites, such as the U.S. National Library of Medicine and to industry conferences and professional journals.